# Novelna

Source: https://onco.cc/companies/novelna/  
OnCo record `novelna` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A start-up developing a low-cost blood test that reads a few proteins, with separate panels for men and women, to detect many early cancers.

## Summary

Novelna, led by founder and chief executive Ashkan Afshin, published its discovery study in BMJ Oncology in 2024. Its Palo Alto location is reported by trade press rather than its own website; its founding year was not found.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Palo Alto, CA
- Type: diagnostics
- Website: https://www.novelna.com/

## Sources

- Official website: https://www.novelna.com/

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/)
- technologies: [Multi-cancer early detection (MCED)](https://onco.cc/technologies/mced/), [Proteomics & phosphoproteomics](https://onco.cc/technologies/proteomics/)
- drugs: [Novelna sex-specific protein test](https://onco.cc/drugs/novelna-protein-test/)
- key papers: [Novel proteomics-based plasma test for early detection of multiple cancers in the general population](https://onco.cc/key-papers/paper-budnik-novelna-proteomics-bmj-oncol-2024/)

---
JSON: https://onco.cc/api/v1/entities/novelna.json